IQ-AI Ltd announced that its wholly owned subsidiary, Imaging Biometrics, has submitted an application to the US Food and Drug Administration (FDA) for breakthrough therapy designation. This regulatory move underscores the company´s efforts to advance the adoption of its emerging medical technologies, which are focused on improving diagnostic imaging in healthcare.
The requested designation is aimed at expediting the development and regulatory review of Imaging Biometrics´ cutting-edge solutions. The company leverages advanced software and data analysis, integrating Artificial Intelligence to enhance imaging for the identification and monitoring of diseases. While the specific condition or therapy targeted by the application was not detailed, breakthrough status is typically reserved for treatments or diagnostics that demonstrate substantial improvement over existing options for serious illnesses.
Receiving the FDA´s breakthrough therapy designation would potentially accelerate the approval process and facilitate closer collaboration with regulatory officials. This could enable a faster route to market for Imaging Biometrics´ technologies, providing patients and clinicians with more effective diagnostic tools. The application marks a significant milestone for IQ-AI Ltd and reflects the growing influence and integration of Artificial Intelligence within the healthcare sector.
